Latest News and Press Releases

~ Second Quarter 2019 Financial Results to be Reported on Friday, August 9, 2019 ~ ~ Company Cancels Previously Scheduled Earnings Call ~ MORRISTOWN, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) --...

~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an Increase of 17 Percent Over the First Quarter of 2019 ~ ~ Anticipates Having...

~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...

~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...

MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...

MORRISTOWN, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...

MORRISTOWN, N.J., April 08, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...

~ Reports Revenue of $96.4 million, Including Net Product Sales of $46.6 million, for the Full-Year 2018 ~ ~ Net Product Sales of $14.6 million for the Fourth Quarter of 2018, up 32 Percent from...

MORRISTOWN, N.J., March 05, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...

– Amendment to Deerfield Facility Agreement Becomes Effective – – John H. Johnson Appointed Permanent Chief Executive Officer – – Company to Report Fourth Quarter and Full Year 2018 Financial...